Table 3.
Neuropeptides secreted under KCl and basal conditions from schizophrenia (SZ) and control (C) iNs.
| Proneuropeptide | Peptide (aa #s) | SZ | SZ | C | C |
|---|---|---|---|---|---|
| KCl | basal | KCl | basal | ||
| ADM | 163–183 | − | − | + | + |
| CHGB | 88–100 | + | + | + | + |
| 293–323 | − | − | + | + | |
| 326–332 | + | + | + | + | |
| 440–452 | − | − | + | − | |
| 440–453 | − | − | + | − | |
| 440–454 | + | − | + | + | |
| 440–456 | − | − | + | + | |
| 441–454 | − | − | + | − | |
| 441–456 | − | − | + | + | |
| 442–452 | − | − | + | − | |
| 442–456 | − | − | + | − | |
| 523–535 | − | − | + | − | |
| 527–533 | − | − | + | + | |
| 527–535 | − | − | + | − | |
| 588–596 | + | + | + | + | |
| 588–597 | + | + | + | + | |
| 588–600 | − | − | + | − | |
| 600–613 | + | + | + | + | |
| NPPC | 24–33 | + | + | + | + |
| 24–72 | − | − | − | − | |
| 34–72 | − | − | + | + | |
| 46–69 | − | − | − | − | |
| NTS | 151–158 | − | − | + | − |
| 151–160 | − | − | + | + | |
| SST | 89–100 | − | − | + | + |
| TMSB10 | 2–44 | + | + | + | + |
| TMSB4X | 2–19 | − | − | + | + |
| 2–44 | + | + | + | + |
Neuropeptides in the media of basal and KCl secretion conditions, released by SZ or C iNs, were identified and quantitated as described in the methods. Proneuropeptide-derived neuropeptides are indicated.